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1  | INTRODUCTION
There has been a steady increase in survival rates of all patients with 
cancer in the UK when compared with the United States and Europe 
with 50% of patients surviving for ten years and beyond (Cancer 
Research UK, 2014). Overall, the approximated two million cancer 
survivors in the UK will increase by 3% per year as the population 
ages (Maddams et al., 2009) and by 2030 the number of cancer sur‐
vivors in the UK is estimated to be four million (Maher & McConnell, 
2011).
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Abstract
Background: Survivors of haematological malignancies endure long‐term effects of 
both treatment and disease. This paper examines factors that influence their quality 
of life through reporting on the results of a survey.
Methods: Survey using previously validated quality of life questionnaires for use in can‐
cer	management.	Participants	were	adults	aged	18	and	over	who	had	completed	treat‐
ment for a haematological malignancy and were between 1 and 5 years post‐treatment.
Findings: A	total	of	131	participants,	median	age	of	66,	completed	questionnaires	
(66% response rate). Significant associations were found between age, global quality 
of life, physical and role functioning. Men reported better physical functioning and 
lower symptom scores than women. Employed participants reported better quality 
of	life.	Increasing	age	was	associated	with	lowest	quality	of	life.	Best	role	functioning	
was also noted in participants who lived beyond 2.5 years following treatment com‐
pletion. The survey suggested a gender difference with men reporting better physical 
functioning, fewer symptoms of pain and less loss of sleep compared with women.
Conclusion: This study contributes to the underdeveloped area of care for and re‐
search into adult haematological cancer survivors. Knowledge and understanding of 
the factors that affect the quality of life of such adults may provide an insight into 
implementation measures.
K E Y WO RD S
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Haematological malignancies are the fourth most frequent can‐
cer type in the developed world, and incidence rates are increasing, 
in part, secondary to our ageing population (Chihara et al., 2014; 
Howlader et al., 2014; Smith, Howell, Patmore, Jack, & Roman, 
2011). B‐cell malignancies such as chronic lymphocytic leukaemia 
(CLL), lymphoma and multiple myeloma (MM) are some of the most 
common haematological malignancies, and this study focused on pa‐
tients	who	were	treated	for	these	conditions.	In	2011,	the	numbers	
of	new	cases	registered	in	the	UK	were	12,783	with	non‐Hodgkin's	
lymphoma	(NHL),	1,845	with	Hodgkin's	lymphoma	(HL),	3,233	with	
CLL and 4,792 with MM (Office for National Statistics [ONS], 2015). 
Although	many	of	 these	malignancies	 are	not	 curable,	 the	 routine	
use of novel and targeted therapies has led to a steady improvement 
in survival rates (Hall, Lynagh, Bryant, & Sanson‐Fisher, 2013; Sant 
et	al.,	2014).	Individuals	treated	for	a	B‐cell	malignancy	are	no	longer	
viewed as victims but as survivors who go on to live for many years 
following	diagnosis	(Aziz	&	Rowland,	2003).
In	England,	 the	5‐year	overall	 survival	 for	men	diagnosed	with	
HL	 during	 2011–2015	 and	 followed	 up	 until	 2016	was	 over	 80%,	
64.9% for NHL, 53.3% for all leukaemia and 51.9% for survivors of 
MM.	During	the	same	period,	women	showed	survival	rates	of	83%	
for	HL,	69.4%	for	NHL,	52.4%	for	all	types	of	leukaemia	and	50.8%	
for	survivors	of	MM	(ONS,	2018).	The	5‐year	survival	for	a	patient	
treated for CLL is 67.0% for men and 73.0% for women in England 
(De	Angelis,	Sant,	&	Coleman,	2014).	These	figures	show	improve‐
ment in survival rates compared to previous years.
Contrary to other malignant diseases, chemotherapy treatment 
regimens for B‐cell malignancies are often more complex and in‐
tense. Hence, they can be more physically and psychologically bur‐
densome	with	prolonged,	 intensive	treatments	(De	Vita,	Lawrence,	
&	Rosenburg,	2008;	Junlen	et	al.,	2015;	Mounier	et	al.,	2015;	Pulte,	
Jansen, Castro, & Brenner, 2016). These treatments have also led to 
significant improvements in survival rates (Mounier et al., 2015; Pulte 
et al., 2016). When a patient is diagnosed with a B‐cell malignancy, 
the treatment not only affects clinical outcomes, but also it can in‐
fluence	 their	 quality	of	 life	 (QoL)	 (van	de	Poll‐Franse	et	 al.,	 2018).	
The physical difficulties (e.g. fatigue, decreased physical capacity) 
and psychosocial problems (e.g. anxiety, depression, stress, insecu‐
rity, grief, decreased self‐esteem, hindered job reintegration, social 
isolation) experienced by these survivors may lead to diminished QoL 
(Gotay,	Holup,	&	Pagano,	2002;	Tomich	&	Helgeson,	2002).
The intense treatment received, especially in patients with hae‐
matological malignancies, can cause deficits in one or more QoL 
domains	 (Hassan	 &	 Abdi‐Valugerdi,	 2014).	 Studies	 investigating	
the long‐term adverse effects of treatment for haematological ma‐
lignancies have identified problems with the eye, endocrine func‐
tion,	 neurosensory	 and	 cardiopulmonary	 impairments	 (Aleman	 &	
van	Leeuwen,	2007;	Hess	et	al.,	2011;	Hodgson,	Grunfeld,	Gunraj,	
&	Giudice,	2010;	Punnett,	Tsang,	&	Hodgson,	2010;	Walsh,	2010).	
Treatment‐related toxicities such as acute confusion and some‐
times metabolic disturbances have been reported (Hallek et al., 
2010;	Hassan	&	Abdi‐Valugerdi,	2014).	Those	who	survive	adverse	
effects of treatment and go on to experience prolonged remission, 
often continue to live with decreased functioning and reduced QoL 
(Efficace,	Novik,	Vignetti,	Mandelli,	&	Cleeland,	2007),	because	they	
continue to deal with the daily challenges of living with the late‐ and 
long‐term adverse effects of treatment and fear of disease recur‐
rence. QoL has, thus, been incorporated as an important outcome 
parameter in clinical trials and in daily clinical practice, enabling 
haematologists to assess the effectiveness of a treatment and 
guide	in	making	tailored	treatment	decisions	(Lopez‐Herce,	Rollon‐
Mayordomo,	Lozano‐Rosado,	Salazar‐Fernandez,	&	Gallana,	2009).
During	the	acute	phase,	most	patients	interact	with	nursing	staff	
on haematology day units for emotional and psychological support 
(Swanson & Koch, 2010). Most haematology departments have ac‐
cess to social workers if required. Therefore, issues that affect phys‐
ical, social or emotional functioning, thereby having an impact on the 
QoL of patients during this phase, are mostly addressed and dealt 
with	(Lobb	et	al.,	2009).	It	is	following	completion	of	treatment	when	
patients feel the lack of such support measures in place (Lobb et 
al., 2009) as they move into long‐term follow‐up in an outpatient 
setting and lose interaction with the healthcare providers. Patients 
have many needs that emerge which can influence their QoL during 
this	time.	In	Dorset,	cancer	care	centres	employ	social	workers	who	
provide services to both inpatients and outpatients departments.
This study sought to examine the QoL of adult survivors treated 
for a B‐cell malignancy, and this cohort appears to be largely an older 
group,	which	represents	the	majority	of	patients	in	Dorset.	Dorset	
is a unique county in the UK as it has the largest population of older 
adults	 with	 28.3%	 being	 65	years	 and	 older	 which	 is	 significantly	
higher	 than	 the	18%	average	 for	England	and	Wales	 (ONS,	2016).	
The high proportion of older cancer survivors in this cohort and 
factors that influence their QoL will provide insight into the future 
ageing UK cancer survivors’ population as a whole. This may, in turn, 
inform future healthcare planning strategies.
2  | METHODS
A	cross‐sectional	design	was	used	in	this	study,	which	was	part	of	a	wider	
mixed‐methods study in a population of patients who were treated for 
a haematological malignancy. This paper only reports the first quantita‐
tive survey data collected between July 2013 and May 2014.
2.1 | Recruitment
Potential participants were identified by treating haematologists at 
three hospital sites. They were contacted by mail and in the outpa‐
tient clinics by their clinicians, and/or they were directly approached 
by the first author in outpatient clinics following confirmation of eli‐
gibility by the clinicians.
Eligible participants were mailed an invitation letter detailing 
the purpose of the study, a demographic questionnaire designed 
specifically for this study, QoL questionnaires namely, the EORTC 
QLQ‐C30,	 the	 EQ‐5D	 and	 a	 postage‐paid	 reply	 envelope.	 Those	
participants approached in outpatient clinics were given the same 
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by hand. To enhance the response rate, a reminder letter and pack 
were sent out after 2 weeks to all the participants who had initially 
received the pack either by hand or by post.
Inclusion	criteria	were	>18	years	of	age,	in	clinical	remission,	as	
determined by treating clinicians. They must have completed treat‐
ment for a B‐cell malignancy (CLL, all lymphomas, MM) 1–5 years 
prior to the commencement of the study, lived within the catchment 
area and/or attended one of the three hospitals. Exclusion criteria 
included cognitive impairment or a history of major psychiatric ill‐
ness and those who lacked the capacity to provide informed con‐
sent. Participants determined by treating clinicians to be too unwell 
to complete questionnaires were also excluded from the study. Basic 
proficiency in the English language was expected, as there were no re‐
sources for translation. The study received ethical approval from the 
National	Research	Ethics	Committee	South	Central—Southampton	A	
(12/SC/0708).	All	participation	was	voluntary,	and	people	returning	
questionnaires were perceived to have implied consent.
2.2 | Demographic data and variables
The demographic questionnaire captured socio‐demographic data 
such as age, gender, marital status, living arrangements, educa‐
tional status, employment status, health status and ethnic origin of 
the participants. Clinical information about diagnosis and time of 
treatment completion was extracted from the medical records or 
hospital database and recorded on an Excel spreadsheet and later 
transferred	onto	SPSS.	Data	were	electronically	stored	securely	on	a	
hospital shared drive which was password protected.
2.3 | The EORTC QLQ‐C30 questionnaire
EORTC QLQ‐C30 is a health‐related QoL questionnaire devel‐
oped by the European Organisation for Research and Treatment of 
Cancer	 (EORTC)	Quality	of	Life	Study	Group	to	assess	the	QoL	of	
patients	with	cancer	(Aaronson	et	al.,	1993;	Sprangers,	Cull,	Bjordal,	
Groenvold,	 &	 Aaronson,	 1993).	 The	 validity	 and	 reliability	 of	 this	
questionnaire	have	been	verified	in	several	studies	(Groenvold,	Klee,	
Sprangers,	&	Aaronson,	1997;	Luckett	et	al.,	2011),	and	the	instru‐
ment is available in several languages (Fayers et al., 2001).
The questionnaire comprises 15 scales with 30 questions in total, 
including physical, emotional, cognitive, social and role functioning, 
fatigue, pain, nausea/vomiting, dyspnoea, insomnia, appetite loss, 
constipation, diarrhoea, financial difficulties and global health sta‐
tus. The questions were rated from 1 to 4 with scores corresponding 
from “not at all” to “very much.” Questions 29 and 30 were rated 
from	1	 to	 7	 (very	 poor	 to	 excellent)	 (Aaronson	 et	 al.,	 1993).	 Each	
rated scale was used to compute a score ranging from 0 to 100 ac‐
cording to the scoring manual of Fayers et al. (2001).
2.4 | EQ‐5D quality of life questionnaire
The	EQ‐5D,	validated	by	the	European	QoL	group,	measures	generic	
health‐related QoL. This questionnaire has been used to measure 
the	QoL	of	individuals	with	long‐term	health	conditions.	It	consists	
of five domains: mobility, self‐care, usual activities, pain/discomfort 
and anxiety/depression. Participants were requested to choose 
from one of the three options (levels) which best described how they 
feel day to day ranging from “no problems” to “extreme problems.” 
The	EQ‐5D	VAS	(visual	analogue	scale)	a	part	of	this	questionnaire	
ranges from 0 to 100 the latter being the best imaginable health 
state. Participants were requested to mark their health status on the 
scale, and this was used as a quantitative measure to report their 
health	outcomes.	Data	from	the	questionnaires	were	analysed	de‐
scriptively	 in	accordance	with	 the	European	Quality	of	Life	Group	
User	Guide	 (Williams,	1990).	The	 three	options	 (levels)	were	com‐
bined into dichotomous variables in SPSS version 19—option 1 (no 
TA B L E  1   Characteristics of survivors of a B‐cell malignancy in 
Dorset,	UK
Characteristics N (%)
Median age in years (interquartile range) 66 (21–95)
Gender
Female 53 (40.5)
Male 78	(59.5)
Marital status
Single/divorced/separated 27 (20.6)
Married/cohabitating 92 (70.2)
Widowed 12 (9.2)
Children
Have children 104 (79.4)
Do	not	have	children 27 (20.6)
Educational status
Up to college 81	(61.8)
Graduate	and	above 44 (33.6
Employment status
Employed 39	(29.8)
Not employed 80	(61.1)
Living status
Living alone 39	(29.8)
Not living alone 92 (70.2)
Ethnic origin (White) 131 (100)
Diagnosis
Leukaemia 14 (10.7)
Lymphoma 102 (77.9)
Myeloma 14 (10.7)
Time since completion of treatment
≤2.5	years 55 (41.9)
>2.5	years 76	(58.1)
Health status
Good 74 (59.6)
Average 35	(28.2)
Poor 15 (12.2)
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problems) was relabelled as “no problems” and option 2 (some prob‐
lems) and option 3 (extreme problems) together as “problems.”
2.5 | EORTC QLQ‐C30 scores and analysis
Descriptive	statistics	were	first	calculated;	numerical	data	were	de‐
scribed using median and interquartile range when skewed. Here, age 
was the only continuous variable that was skewed. Non‐parametric 
Kendall's	tau	correlation	coefficient	was	used	to	determine	associa‐
tions between age and QoL subscales with a two‐tailed significance 
test (p < 0.05) to assess the strength of the dependence of two vari‐
ables (Bland, 2000) and data collected from the EORTC QLQ‐C30 
questionnaires were considered ordinal, and QoL measurement was 
considered nominal ordered. The associations between socio‐demo‐
graphic, clinical factors and QoL subscales were determined using 
the Mann–Whitney U test. This test is used when two independent 
random samples are compared and when data are ordinal as in this 
sample (Bland, 2000). Raw scores of this questionnaire were trans‐
formed to a linear scale ranging from 0 to 100. Higher scores rep‐
resent higher functioning and QoL and a higher level of symptoms. 
Scoring was undertaken using directions from the EORTC scoring 
manual	 (Kaasa	 et	 al.,	 1995;	 Groenvold	 et	 al.,	 1997;	 Gulbrandsen,	
Hjermstad,	Wisloff,	&	Nordic	Myeloma	Study	Group,	2004).
2.6 | EQ‐5D scoring and analysis
The independent samples t test was used to determine associations 
between	 age	 and	 the	EQ‐5D	dimensions.	 This	 test	was	used	 as	 it	
identifies statistical differences between the means of two groups 
of	reasonable	size	(Petrie	&	Sabin,	2009).	The	independent	sample	
t test requires the assumption of homogeneity of variance. The test 
that	 is	 used	 for	 this	 assumption	 is	 Levene's	 test.	 The	 associations	
between	age	and	the	EQ‐5D	VAS	were	determined	using	Spearman's	
rank correlation coefficient as age was considered non‐normal. 
This test is a non‐parametric test and has been used to measure 
the strength and direction of two variables (Petrie & Sabin, 2009). 
Associations	between	the	socio‐demographic	variables	and	the	di‐
chotomised	EQ‐5D	dimensions	were	determined	using	cross‐tabula‐
tions. Row percentages were chosen as they were more useful and 
appropriate	 in	answering	 the	 research	question.	 If	one	cell	had	an	
expected	 count	 of	 <5,	 then	 Fisher's	 exact	 test	 was	 used	 (Foster,	
Jefferies, & Foster, 2014).
3  | RESULTS
3.1 | Patient and clinical characteristics
A	total	of	200	participants	were	invited	to	take	part	resulting	in	131	
completed questionnaires with a response rate of 66%. The median 
(interquartile range) age of participants was 66.0 years (21.0–95.0) 
reflecting the prevalence of these types of haematological malignan‐
cies	in	an	older	population.	Demographic	and	clinical	characteristics	
of participants are summarised in Table 1.
The proportion of men (59.5%) was more than women in the sam‐
ple enrolled in the study. More than 70% of the sample was married 
or	cohabitating	but	nearly	one‐third	(29.8%)	of	participants	were	liv‐
ing alone at the time of data collection; the majority (79.4%) had chil‐
dren.	Almost	two‐thirds	(61.8%)	of	the	sample	had	been	educated	to	
graduate level, and nearly two‐thirds (61.1%) of the enrolled partic‐
ipants	were	not	 in	employment	and/or	retired.	All	 the	participants	
were Caucasian. The main disease type represented in the sample 
enrolled	was	NHL	and	HD	(78%);	nearly	11%	of	the	respondents	re‐
ported having been treated for MM, and similarly, a tenth of them 
was treated for CLL (10.7%). More than half of the people enrolled 
(58%)	had	completed	treatment	for	a	B‐cell	malignancy	more	than	
two and a half years previously. Less than two‐thirds (59.6%) and 
almost 30% of the respondents rated their general health status as 
good and average, respectively, whereas 12.2% of participants rated 
their	general	health	status	as	poor.	All	the	enrolled	participants	were	
in remission at the time of data collection.
3.2 | EORTC QLQ‐C30 questionnaire
The correlation between the QoL domains in the EORTC QLQ‐C30 
questionnaire and the socio‐demographic characteristics are pre‐
sented	in	Table	2.	Age	showed	a	significant	negative	correlation	with	
global QoL, physical functioning and role functioning. Significant 
QoL differences were observed by gender with men reporting bet‐
ter physical functioning (p	=	0.041)	when	 compared	 to	women.	 In	
addition, men reported fewer symptoms of pain (p = 0.000) and less 
sleep loss (p = 0.001) compared with women. Employed participants 
experienced better physical functioning (p = 0.000), role function‐
ing (p = 0.000) and cognitive functioning (p = 0.000), social function 
(p = 0.0007) compared to those who were not employed (as above). 
Unemployed participants experienced more fatigue (p = 0.000), 
more symptoms of pain (p = 0.000), dyspnoea (p = 0.003), sleep 
Dimension
No problems Problems
Number Percentage Number Percentage
Mobility 84 64.6 46 35.4
Self‐care 116 89.9 13 10.1
Usual activity 82 64.1 46 35.9
Pain/discomfort 80 61.5 50 38.5
Anxiety/depression 96 73.8 34 26.2
TA B L E  3   Survivors treated for a B‐cell 
malignancy who reported any problems in 
Dorset,	UK	(EQ‐5D)
6 of 11  |     IMMANUEL Et AL.
loss (p = 0.001), appetite (p = 0.031) and constipation (p = 0.031) 
compared with those employed. Other variables such as “time since 
completion of treatment”, “living arrangements” and “educational 
status” did not have a significant impact on other QoL domains.
3.3 | EQ‐5D QoL questionnaire
Associations	between	the	QoL	domains	and	the	socio‐demographic	
characteristics	 are	presented	 in	Table	3.	Amongst	 the	 five	dimen‐
sions, fewest problems were reported for self‐care (10.1%) and 
the	 most	 for	 pain/discomfort	 (38.5%),	 followed	 by	 usual	 activity	
(35.9%).	 Almost	 two‐thirds	 (61.5%)	 of	 participants	 reported	 being	
problem‐free.
The proportion of participants reporting any/no problems in the 
five	dimensions	of	the	EQ‐5D	descriptive	system	is	shown	in	Table	4.	
According	to	the	EQ‐5D‐3L	questionnaire,	most	participants	did	not	
report problems with self‐care or anxiety/depression. However, 
a high proportion of participants reported problems with mobility 
(35.4%),	usual	activities	(35.9%)	and	pain/discomfort	(38.5%).
There was little difference by gender in mobility, self‐care, usual 
activities and anxiety/depression, and two‐thirds (66.2%) of men and 
62.3%	of	women	reported	no	problems	with	mobility.	Most	(90.8%	
of	men/88.7%	of	women)	 reported	no	problems	with	self‐care	ac‐
tivities,	and	68%	of	men	and	58.5%	of	women	had	no	problems	in	
continuing with usual activities. However, there were significant 
gender differences in reporting of pain/discomfort. The proportion 
of men who reported no problems with pain/discomfort (70.1%) 
was higher than the proportion of women (49.1%) who reported 
no problems with the same symptom. This difference was statisti‐
cally significant with a p‐value	 of	 0.015.	 All	 participants	 reported	
the lowest proportion of problems in the self‐care dimension (10%). 
Participants with children were more likely to report problems with 
mobility	(40.0%)	than	those	without	children	(16.0%).	A	statistically	
significant difference was observed here with a p‐value of 0.024. 
Participants with children were less likely to report no problems with 
usual	activities	 (59.2%)	than	those	without	children	 (84.0%)	with	a	
p‐value of 0.021. The variable that was significant for all dimensions 
was employment. Employed participants reported no problems with 
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Mobility Self‐care Usual activities Pain/Discomfort Anxiety/Depression
No problem % 
[n]
Problem % 
[n] Total % [n] p Value
No problem 
% [n] Problem % [n] Total % [n] p Value
No 
problem % 
[n]
Problem 
% [n] Total % [n] p Value
No problem 
% [n]
Problem 
% [n] Total % [n] p Value
No problem 
% [n]
Problem 
% [n] Total % [n] p Value
Gender
Male 66.2 [51] 33.8	[26] 100.0 [77] 0.642 90.8	[69] 9.2 [7] 100.0 [76] 0.695 68.0	[51] 32.0 [24] 100.0 [75] 0.269 70.1 [54] 29.9 [23] 100.0 [77] 0.015*  76.6 [59] 23.4	[18] 100.0 [77] 0.385
Female 62.3 [33] 37.7 [20] 100.0 [53] 88.7	[47] 11.3 [6] 100.0 [53] 58.5	[31] 41.5 [22] 100.0 [53] 49.1 [26] 50.9 [27] 100.0 [53] 69.8	[37] 30.2 [16] 100.0 [53]
Treatment Compla 
≤2.5	years 56.0	[28] 44.0 [22] 100.0 [50] 0.690 86.0	[43] 14.0 [7] 100.0 [50] 0.102b  58.0	[29] 42.0 [21] 100.0 [50] 0.154 62.0 [31] 38.0	[19] 100.0 [50] 0.906 72.0 [36] 28.0	[14] 100.0[50] 0.547
>2.5	years 72.3 [47] 27.7	[18] 100.0 [65] 95.3 [61] 4.7 [3] 100.0 [64] 70.8	[46] 29.2 [19] 100.0 [65] 63.1 [41] 36.9 [24] 100.0 [65] 76.9 [50] 23.1 [15] 100.0 [65]
Living
Living alone 69.2 [27] 30.8	[12] 100.0 [39] 0.471 92.3 [36] 7.7 [3] 100.0 [39] 0.753b  69.2 [27] 30.8	[12] 100.0 [39] 0.420 69.2 [27] 30.8	[12] 100.0 [39] 0.238 74.4 [29] 25.6 [10] 100.0 [39] 0.931
Not living alone 62.6 [57] 37.4 [34] 100.0 [91] 88.9	[80] 11.1 [10] 100.0 [90] 61.8	[55] 38.2	[34] 100.0	[89] 58.2	[53] 41.8	[38] 100.0 [91] 73.6 [67] 26.4 [24] 100.0 [91]
Children
Yes 60.0 [63] 40.0 [42] 100.0 
[105]
0.024*  88.5	[92] 11.5 [12] 100.0 [104] 0.461b  59.2 [61] 40.8	[42] 100.0 [103] 0.021*  58.1	[61] 41.9 [44] 100.0 [105] 0.098 71.4 [75] 28.6	[30] 100.0 [105] 0.199
No 84.0	[21] 16.0 [4] 100.0 [25] 96.0 [24] 4.0 [1] 100.0 [25] 84.0	[21] 16.0 [4] 100.0 [25] 76.0 [19] 24.0 [6] 100.0 [25] 84.0	[21] 16.0 [4] 100.0 [25]
Education
Up to College 62.5 [50] 37.5 [30] 100.0	[80] 0.373 91.1 [72] 8.9	[7] 100.0 [79] 0.754b  64.1 [50] 35.9	[28] 100.0	[78] 0.841 60.0	[48] 40.0 [32] 100.0	[80] 0.516 75.0 [60] 25.0 [20] 100.0	[80] 1.000
Graduate	and	above 70.5 [31] 29.5 [13] 100.0 [44] 88.6	[39] 11.4 [5] 100.0 [44] 65.9 [29] 34.1 [15] 100.0 [44] 65.9 [29] 34.1 [15] 100.0 [44] 75.0 [33] 25.0 [11] 100.0 [44]
Employment
Employed 89.5	[34] 10.5 [4] 100.0	[38] <0.001 100.0	[38] 0.0 [0] 100.0	[38] 0.009b  92.1 [35] 7.9 [3] 100.0	[38] <0.001*  78.9	[30] 21.1	[8] 100.0	[38] 0.004*  86.8	[33] 13.2 [5] 100.0	[38] 0.035* 
Not employed 50.0 [40] 50.0 [40] 100.0	[80] 84.8	[67] 15.2 [12] 100.0 [79] 48.7	[38] 51.3 [40] 100.0	[78] 51.3 [41] 48.8	[39] 100.0	[80] 68.8	[55] 31.3 [25] 100.0	[80]
Health
Good 100.0 [25] 0.00 [0] 100.0 [25] <0.001 100.0 [25] 0.0 [0] 100.0 [25] <0.001 100.0 [25] 0.0 [0] 100.0 [25] <0.001 100.0 [25] 0.0 [0] 100.0 [25] <0.001 96.0 [24] 4.0 [1] 100.2[5] <0.001
Average 100.0 [25] 0.00 [0] 100.0 [25] 100.0 [25] 0.00 [0] 100.0 [25] 100.0 [25] 0.00 [0] 100.0 [25] 100.0 [25] 0.00 [0] 100.0 [25] 100.0 [25] 0.00 [0] 100.0 [25]
Poor 100.0 [25] 0.00 [0] 100.0 [25] 100.0 [25] 0.00 [0] 100.0 [25] 100.0 [25] 0.00 [0] 100.0 [25] 100.0 [25] 0.00 [0] 100.0 [25] 100.0 [25] 0.00 [0] 100.0 [25]
Bold values represent statistically significant difference with a p < 0.001.
aDuration	of	completion	of	treatment.	bFisher's	exact	test.	*Statistically	significant.	
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mobility (p‐value < 0.001) when compared to unemployed or retired 
participants.	All	employed	participants	 reported	no	problems	with	
self‐care. Most (92.1%) employed participants reported no prob‐
lems with carrying out usual activities with the differences being 
statistically significant (p‐value	<	0.001).	 Most	 (78.9%)	 employed	
participants did not report any pain/discomfort (p	=	0.004).	Anxiety/
depression	was	not	a	problem	reported	in	86.8%	of	participants	who	
were employed (p = 0.035).
4  | DISCUSSION
4.1 | EORTC QLQ C30
The key findings of the importance of gender for pain, having chil‐
dren for mobility and usual activities, employment status and health 
status for all dimensions are presented. This study addressed issues 
that	were	predominant	amongst	the	survivors.	It	explored	the	impact	
of selected socio‐demographic variables on the QoL of survivors of 
B‐cell	malignancies.	Increasing	age	was	associated	with	lower	QoL.	
These findings support those of Priscilla et al. (2011) who reported 
reduced QoL with impaired physical and role functioning in older 
patients	with	a	haematological	cancer.	A	similar	trend	is	seen	in	the	
study conducted by SlovacekSlovackova, Pavlik, and Jebavy (2007).
Men reported lower pain scores and less loss of sleep than 
did women. Studies by Mellon, Northouse, and Weiss (2006) and 
Matthews, Tejeda, Johnson, Berbaum, and Manfredi (2012) add sup‐
port to these findings where women reported lower QoL than men. 
However, these findings were not specific to survivors of a haema‐
tological	malignancy	 but	 encompassed	 all	 cancer	 survivors.	 A	 sig‐
nificant difference was seen in the domain of physical functioning 
with men reporting higher levels of physical functioning (p < 0.05) 
in these studies.
Employed survivors reported significantly better physical func‐
tioning and social functioning and fewer role limitations and symp‐
toms	 than	 those	 who	 were	 not	 employed.	 In	 general,	 employed	
participants, therefore, reported a much better QoL than those 
who were not employed. To add, most of the participants with more 
symptoms of fatigue, pain, sleep loss, appetite loss and constipation 
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were unemployed or retired (Table 2). Participants who lived beyond 
two and a half years following completion of treatment for haema‐
tological malignancy reported better role functioning than those 
who completed treatment less than 2.5 years previously (p=<0.048).	
Other QoL dimensions did not show significant associations with 
time since completion of treatment. No significant associations were 
found between the QoL dimensions and the marital status and/or 
living arrangements of participants.
The correlation between the QoL domains in the EORTC 
QLQ‐C30 questionnaire and the socio‐demographic character‐
istics	 are	presented	 in	Table	2.	Age	 showed	a	 significant	 negative	
correlation with global QoL, physical functioning and role func‐
tioning. Significant QoL differences were observed in gender with 
men reporting better physical functioning (p = 0.041) compared 
with	 women.	 In	 addition,	 men	 reported	 fewer	 symptoms	 of	 pain	
(p = 0.000) and less sleep loss (p = 0.001) compared with women. 
Employed participants experienced better physical functioning 
(p = 0.000), role functioning (p = 0.000) and cognitive functioning 
(p = 0.000) compared with those who were not employed/retired. 
Unemployed participants experienced more fatigue (p = 0.000), 
more symptoms of pain (p = 0.000), dyspnoea (p = 0.003), sleep loss 
(p = 0.001), appetite (p = 0.031) and constipation (p = 0.031). Other 
variables such as “time since completion of treatment,” “living ar‐
rangements” and “educational status” did not have a significant im‐
pact on the other QoL domains. Overall, younger participants, men 
and those in employment reported better quality of life.
4.2 | EQ‐5D questionnaire
Less than 30% of participants reported problems with self‐care and 
anxiety/depression. The present findings seem to be consistent with 
other studies amongst patients with lymphoma who had received 
chemotherapy (Cull et al., 1996) and patients with acute leukaemia 
with anxiety and depression showing an improvement towards the 
end	of	treatment	and	after	(Zittoun,	Achard,	&	Ruszniewski,	1999).	
Another	study	by	Heinonen	et	al.	(2001)	suggested	that	the	level	of	
anxiety and depression was lower in the post‐treatment follow‐up 
phase than in the active treatment phase for peripheral stem cell 
transplant recipients. However, over 35% of participants reported 
having problems with mobility, usual activity and pain or discomfort. 
A	 study	 of	 cervical	 cancer	 survivors	 showed	 comparable	 results	
(Lang, Chuang, Shun, Hsieh, & Lan, 2010) for the self‐care dimen‐
sion; however, only <10% of participants had problems with mobility.
Pain or discomfort was the most frequently reported symptom 
amongst all the other dimensions in this group of survivors of hae‐
matological	malignancy	with	 38.5%	 of	 survivors	 reporting	moder‐
ate or severe pain or discomfort. Women reported more pain or 
discomfort	when	compared	to	men	with	>50%	of	women	reporting	
moderate or severe levels of pain/discomfort, whereas <30% of men 
reported moderate/severe problems with pain/discomfort. These 
findings were consistent with the findings of earlier studies (Baker, 
Haffer,	&	Denniston,	2003;	Matalqah,	Radaideh,	Yusoff,	&	Awaisu,	
2011; Oh, Han, Park, Park, & Chung, 2014).
Performing usual activity was the second most frequently re‐
ported problem in this group of survivors (35.9%) followed by mo‐
bility dimension which was the next frequently reported dimension 
where participants reported moderate or severe problems (35.4%). 
A	study	by	Oh	et	al.	(2014)	also	showed	similar	results	with	self‐care	
being the lowest reported dimension with moderate to severe prob‐
lems. These symptoms may also be attributed to a predominantly 
older population. This indicates that even if the survivors are disease 
free, they may experience debilitating symptoms of pain/discomfort 
and other issues such as mobility and performing a usual activity to 
a certain degree which can have a significant impact on their quality 
of life. These factors can also be attributed to an ageing population 
as	in	Dorset.	It	is	therefore	very	important	as	healthcare	providers	to	
pay attention to and address these needs.
The main strength of the study was that it was representative of 
an ageing population with haematological malignancies of the whole 
UK.	A	high	completion	and	return	rate	of	the	questionnaires	was	also	
strength of this study. The use of a combination of validated generic 
and disease‐specific questionnaires that enabled capturing of data 
in greater detail was also strength of this study. However, it is im‐
portant	to	address	some	limitations	here.	Due	to	the	cross‐sectional	
nature of the study, it has not been possible to explore the changes 
in QoL over time as in longitudinal studies. The participants’ mental 
status at the time of completion of questionnaires may have influ‐
enced	their	answers	and	the	EQ‐VAS	scores.	Based	on	the	sample	of	
131 in total, the number of participants with a diagnosis of MM and 
CLL was relatively small, and it did not allow for comparison of the 
QoL amongst the groups. The number of participants with MM and 
CLL was 15 each. Those with a diagnosis of any type of lymphoma 
were predominant in this population, which may not be represen‐
tative of the quality of life assessment of the smaller groups (CLL 
and MM). The limitation of the EORTC QLQ‐C30 questionnaire is 
that it provides an overview of health‐related QoL in general and not 
a greater understanding of the different aspects of QoL that may 
affect patients who have completed treatment for a haematological 
malignancy.	As	 it	 gathers	 the	 subjective	experience	of	 the	patient	
about their symptoms and functions, it can be interpreted in various 
ways; pain may be due to malignant disease or another co‐morbid 
condition.	A	validated	questionnaire	that	explores	 in	greater	detail	
specific issues pertinent to survivors may have been immensely use‐
ful	but	none	was	available	at	the	start	of	the	study.	Another	consid‐
eration is the multiple significance tests and that differences have 
been found by chance.
5  | CONCLUSION
Men and those in employment who have completed treatment 
for haematological malignancy reported better QoL in this study. 
Women reported lower physical functioning, more pain and less 
sleep	when	compared	 to	men.	Age	had	a	 significant	negative	 cor‐
relation with global QoL, physical and role functioning. These issues 
need to be addressed when planning long‐term survivorship care as 
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it must be tailored to suit individual needs. With the gender differ‐
ences in QoL identified, different clinical approaches are warranted 
in male and female survivors. These different approaches may en‐
able healthcare providers to provide tailored treatment modalities 
to	optimise	outcomes	and	improve	QoL.	In	order	to	provide	ongoing	
support and set up robust systems in the cancer care pathway, it 
is very important to understand the experiences of these survivors 
and the possible long‐term effects, the malignancy and its treatment 
entails.	Assessment	at	an	early	stage	will	prepare	healthcare	provid‐
ers to determine the level of support each patient may require in 
the survivorship phase. To optimise QoL for these survivors, health‐
care services must focus and target on the disease and treatment 
associated sequelae that may influence a patient in the survivorship 
phase. Structured survivorship care models can be implemented to 
further	enhance	the	quality	of	lives	of	these	survivors.	It	is	evident	
that patients’ needs and concerns may change along their cancer 
spectrum.	It	is	important	to	utilise	assessment	tools	that	report	con‐
cerns of survivors and enable conversations with healthcare provid‐
ers with “care planning,” continued communication between primary 
care physicians and haematologists, access to health and well‐being 
services is recommended as the optimal approach in delivering per‐
sonalised	survivor	care.	A	further	validated	questionnaire	that	spe‐
cifically addresses needs pertinent to survivors of a haematological 
malignancy is required. These questionnaires will facilitate the cap‐
turing of such needs and may enable the development of care mod‐
els. This study warrants the investigation of a systematic long‐term 
follow‐up care model in larger studies.
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